Methylphenidate (Ritalin)-associated cataract and glaucoma

Journal of the Chinese Medical Association

Volumn 69, Issue 12, 2006, Pages 589-590

  Lu, Chao Kung ^a   Kuang, Tung Mei ^a   Chou, Joe Ching Kuang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cataract; Glaucoma; Methylphenidate; Ritalin

Indexed keywords

ACETAZOLAMIDE; CARTEOLOL; LATANOPROST; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; BLURRED VISION; CASE REPORT; CATARACT; CHILD; DRUG WITHDRAWAL; EYE EXAMINATION; GLAUCOMA; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANTATION; MALE; OPHTHALMOSCOPY; PHACOEMULSIFICATION; SCOTOMA; SLIT LAMP; SYMPTOMATOLOGY; TRABECULECTOMY; VISUAL ACUITY;

EID: 33846333119     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70335-1     Document Type: Article

References (5)

1. Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf 1997;7:143-8.
2. Bartlik B, Harmon G. Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch Gen Psychiatry 1997;54:188-9.
3. Shahzad S, Suleman MI, Shahab H, Mazour I, Kaur A, Rudzinskiy P, Lippmann S. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002;43:354-9.
4. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37:457-70.
5. Oshika T. Ocular adverse effects of neuropsychiatric agents: incidence and management. Drug Saf 1995;12:256-63.